Company news
Palvella Therapeutics, Inc. news in 2026
Palvella Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget’s Disease (EMPD)
November 19, 2026
Palvella Therapeutics to Host Webcast to Introduce New QTORIN™ Program
November 18, 2026
Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
November 5, 2026
Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference
November 3, 2026
Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026
October 29, 2026
Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set
October 28, 2026
Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
October 15, 2026
Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
October 13, 2026
Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
October 12, 2026
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
September 28, 2026
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
September 2, 2026
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 5, 2026
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 4, 2026
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
July 29, 2026
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
July 28, 2026
FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
June 22, 2026
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
June 2, 2026
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
June 2, 2026
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
May 26, 2026
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
May 21, 2026
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
May 15, 2026
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
May 13, 2026
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
May 4, 2026
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
April 30, 2026
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
April 20, 2026
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
April 12, 2026
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
April 6, 2026
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
March 30, 2026
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
March 29, 2026
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
March 26, 2026
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
March 23, 2026
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
March 22, 2026
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
March 15, 2026
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
March 9, 2026
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
March 2, 2026
Palvella Therapeutics Announces Pricing of Upsized Public Offering
February 25, 2026
Palvella Therapeutics Announces Proposed Public Offering
February 24, 2026
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
February 23, 2026
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
February 23, 2026
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
February 2, 2026
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
January 9, 2026
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
January 7, 2026
Calls in 2026
- Palvella Therapeutics (NASDAQ:PVLA) Q3 2026 Earnings Call
Nov 5, 2026
Transcript - Palvella Therapeutics (NASDAQ:PVLA) Q2 2026 Earnings Call
Aug 4, 2026
Transcript - Palvella Therapeutics (NASDAQ:PVLA) Q1 2026 Earnings Call
May 7, 2026
Transcript - Palvella Therapeutics (NASDAQ:PVLA) Q4 2025 Earnings Call
Mar 31, 2026
Transcript
Decks in 2026
- Corporate Update (November 2026)
Corporate update · 20 slides · Nov 19, 2026
- Q3 2026 Earnings Presentation
Earnings · 22 slides · Nov 5, 2026
- Q2 2026 Earnings Presentation
Earnings · 25 slides · Aug 4, 2026
- Investor Presentation (July 2026)
Investor deck · 61 slides · Jul 14, 2026
- ISSVA World Congress 2026
Conference · 14 slides · May 20, 2026
- Q1 2026 Earnings Presentation
Earnings · 30 slides · May 7, 2026
- Investor Presentation (April 2026)
Investor deck · 48 slides · Apr 7, 2026
- FY2025 Earnings Presentation
Earnings · 25 slides · Mar 31, 2026
- Technical Presentation (February 2026)
Technical · 26 slides · Feb 24, 2026
- Investor Presentation (January 2026)
Investor deck · 56 slides · Jan 29, 2026